Walgreens Defends Board’s Response to Insulin Pen Price Scheme

Walgreens Boots Alliance Inc. took steps to improve oversight of its insulin billing practices in the months before reaching a $209 million settlement with the federal government, a company lawyer said Monday in a bid to toss a shareholder lawsuit.

A Walgreens shareholder claims the pharmacy giant’s board ignored red flags about overcharging the federal government for insulin pens after it had abandoned reforms put in place as part of a 2008 settlement for separate over-billing charges.

There’s no connection between any earlier settlement and the federal investigation that the directors first learned about in early 2017, Martin Crisp ...